In a major development for cardiovascular research, Nigerian-born biomedical scientist, Comfort Williams Ekom is making significant strides in understanding pulmonary arterial hypertension (PAH), a deadly and complex disease that affects the arteries of the lungs and burdens the heart.

Her pioneering research is unlocking new possibilities for targeted treatments and precision medicine, particularly in genetically vulnerable populations.

Currently a doctoral candidate at New York Medical College, Williams is investigating the role of plasminogen activator inhibitor-1 (PAI-1) in the progression of PAH. Her findings highlight how PAI-1 disrupts the normal function of Pulmonary Arterial Smooth Muscle Cells (PASMCs), promoting cell migration and senescence, two key processes that contribute to the irreversible remodeling of blood vessels seen in PAH.

“PAH has one of the highest mortality rates among cardiovascular diseases, and yet the molecular causes remain poorly understood,” Williams said in an interview. “My research is helping to uncover how PAI-1 acts as a key promoter of smooth muscle cell dysfunction, which could be a game-changer in treatment approaches.”

Ekom’s research also explores a novel genetic link: the relationship between PAI-1 and glucose-6-phosphate dehydrogenase (G6PD) polymorphisms, genetic variants commonly found in African and Mediterranean populations. Her findings suggest that individuals with specific G6PD variants may be at higher risk of developing PAH.

“Understanding how genetic differences shape disease progression is key to developing personalised therapies,” she explained. “We’re moving away from one-size-fits-all medicine.”

Supported by NIH R01-funded projects, Ekom has employed advanced gene-editing techniques, including CRISPR to develop rat models carrying G6PD variants. These models are used to investigate how environmental and genetic factors interact to influence PAH onset and severity. Her in vitro experiments have further shown that PAI-1 not only reduces cell proliferation but also accelerates senescence and migration in PASMCs, positioning PAI-1 as a promising target for future drug therapies.

In recognition of her groundbreaking work, Williams received the Poster Presenter Award at the 36th Annual Graduate Student Research Forum in March 2025. She was later invited to speak at the American Physiological Society (APS) Summit in Baltimore, where she shared the stage with leading researchers from across the globe.

“Being invited to share this work on an international stage was deeply affirming,” Williams said.

“But the real reward is contributing to a future where fewer people suffer from this devastating disease.”

Cardiovascular diseases remain the world’s leading cause of death, claiming nearly 18 million lives annually. As global health leaders look toward more tailored treatment approaches, Williams’s research stands out for its blend of molecular innovation and real-world relevance, especially in the context of underserved and genetically diverse populations.

Through her focus on PAI-1, genetic susceptibility, and advanced modeling techniques, Ekom is redefining how scientists approach the diagnosis and treatment of PAH. Her work not only positions her as a rising leader in cardiovascular science but also offers a beacon of hope for millions affected by pulmonary arterial hypertension worldwide.